TipHub

213.17

+4.2 +2.01%

As of 27 Jul 2026 · delayed

NSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-05-29
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Sun Pharma Advanced Research Company Ltd. (SPARC)

Volume: 9,38,471Avg Vol 1W: 14,65,068.8Avg Vol 1M: 26,90,175.4552W Range:108289
Key Ratios
Checked 1d ago
Market Cap₹7,399 Cr
Current Price₹213.17
Previous Close₹208.97
High / Low (52w)₹289 / ₹108
Volume9,38,471
Avg Vol (1W)14,65,068.8
Avg Vol (1M)26,90,175.45
Stock P/E-14.03
Book Value₹-6.68
Dividend Yield
ROE0%
ROA
Revenue (TTM)₹74 Cr
Revenue Growth
Profit Margin
Total Debt₹100 Cr
Shares Outstanding
Face Value₹1
EPS (TTM)₹-10.55
P/B-22.16
Debt / Equity0
50 DMA₹231.84
200 DMA₹160.66
Day change+2.01%
SurveillanceLT-ASM · ASM 1
Price Chart
213.17 38.85% · 1Y
27810912.2Cr
2025-07-29
2026-07-27

20-day avg volume: 26.9L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 66% YoY.
  • Company is loss-making at the latest annual result.
  • Negative book value per share.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹17 Cr₹13 Cr₹15 Cr₹27 Cr₹10 Cr₹8 Cr₹8 Cr₹1,853 Cr
EBITDA₹-95 Cr₹-106 Cr₹-77 Cr₹-56 Cr₹-46 Cr₹-68 Cr₹-59 Cr₹1,773 Cr
Net Profit₹-96 Cr₹-107 Cr₹-80 Cr₹-60 Cr₹-52 Cr₹-76 Cr₹-80 Cr₹1,761 Cr
EPS
Profit & Loss (Annual)
MetricDec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026
Revenue₹15 Cr₹27 Cr₹74 Cr₹10 Cr₹8 Cr₹8 Cr₹1,853 Cr₹1,890 Cr
EBITDA₹-77 Cr₹-56 Cr₹-334 Cr₹-46 Cr₹-68 Cr₹-59 Cr₹1,772 Cr₹1,600 Cr
Net Profit₹-80 Cr₹-61 Cr₹-343 Cr₹-52 Cr₹-76 Cr₹-81 Cr₹1,761 Cr₹1,553 Cr
EPS-10.5547.86
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹273 Cr₹230 Cr₹280 Cr₹830 Cr₹515 Cr₹336 Cr₹2,171 Cr
Total Liabilities₹291 Cr₹398 Cr₹249 Cr₹317 Cr₹389 Cr₹552 Cr₹832 Cr
Equity₹-19 Cr₹-168 Cr₹31 Cr₹513 Cr₹126 Cr₹-217 Cr₹1,339 Cr
Total Debt₹6 Cr₹113 Cr₹0 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-150 Cr₹-213 Cr₹-74 Cr₹-425 Cr₹-369 Cr₹-270 Cr
Investing₹2 Cr₹-29 Cr₹-548 Cr₹392 Cr₹158 Cr₹-23 Cr
Financing₹159 Cr₹229 Cr₹617 Cr₹42 Cr₹199 Cr₹261 Cr
Free Cash Flow₹-150 Cr₹-213 Cr₹-74 Cr₹-425 Cr₹-369 Cr₹-270 Cr
Shareholding
Promoter 65.67% Institutions 2.57% Public 31.76%
Efficiency & Working Capital
ROCE80.9%
Interest Coverage46.5
Dividend Payout
Debtor Days82 d
Inventory Days0 d
Payable Days579 d
Cash Conversion Cycle-498 d
Working Capital Days82 d
Shareholding Details

As of 2026-06-30

Promoter65.7%
FII3.9%
DII0.1%
Institutions4%
Public30.3%
Promoter Pledge0%
No. of Shareholders1,41,957
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026May 2026May 2026Jun 2026
Promoters65.7%65.7%65.7%65.7%65.7%65.7%65.7%65.7%65.7%65.7%65.7%65.7%
FIIs3.2%2.6%2.1%2.2%1.4%1.5%1.8%2%2%2.5%2.5%3.9%
DIIs0.8%0.2%0.2%0.6%1.1%1%1%0.8%0.9%0.1%0.1%0.1%
Public30.3%31.5%32%31.5%31.8%31.9%31.5%31.5%31.4%31.8%31.8%30.3%
Promoter Pledge2.8%2.8%2.8%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,02,7431,25,1841,28,2051,31,0341,42,8641,40,7241,36,9971,44,8101,40,6251,37,5381,37,5381,41,957
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Shanghvi Finance Private LimitedShareholding of Promoter and Promoter Group42.3%13.72 Cr
Dilip.s.shanghviShareholding of Promoter and Promoter Group19.1%6.18 Cr
Sun Pharmaceutical Industries Key Employees Benefit TrustPublic Shareholding3.2%1.03 Cr
Aditya Medisales LimitedShareholding of Promoter and Promoter Group1.5%48,88,126
Raksha Sudhir ValiaShareholding of Promoter and Promoter Group1.3%41,45,231
Paresh Mohanlal ParekhPublic Shareholding1.1%36,51,837
Vijay Mohanlal ParekhPublic Shareholding1.1%36,65,304
Enam Securities Private LimitedPublic Shareholding1%33,70,786
Sudhir Vrundavandas ValiaShareholding of Promoter and Promoter Group0.6%18,33,951
Unimed Investments LimitedShareholding of Promoter and Promoter Group0.4%12,67,963
Vibha Dilip ShanghviShareholding of Promoter and Promoter Group0.3%10,63,236
Aalok Dilip ShanghviShareholding of Promoter and Promoter Group0.1%3,50,162
Vidhi Dilip ShanghviShareholding of Promoter and Promoter Group0.1%3,44,081
Shanghvi Family & Friends Benefit TrustShareholding of Promoter and Promoter Group0.1%1,54,922
Kumud Shantilal ShanghviShareholding of Promoter and Promoter Group0%38,795
Flamboyawer Finance Private LimitedShareholding of Promoter and Promoter Group0%2,543
Shanghvi Universal Private LimitedShareholding of Promoter and Promoter Group0%1,887
Sun Petro Private LimitedShareholding of Promoter and Promoter Group0%1,751
Board of Directors
NameDesignationYear
T RajamannarNon Executive Director2025
Bhavna DoshiIndependent Director2025
Ferzaan EngineerIndependent Director2025
Robert SpiegelIndependent Director2025
Dilip S ShanghviChairman (Non-Executive)2025
Kajal Damania.Company Sec. & Compli. Officer2025
Vidhi ShanghviNon Executive Director2025
Rekha Gopal WarriarIndependent Director2025
Venkateswarlu JastiIndependent Director2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals Research & Developm₹0 Cr
Segments — Geography
RegionRevenueShare
Within India₹38 Cr97.2%
Outside India₹1 Cr2.8%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹1433232
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202552006213271
202551000121171
2025000000
Insider / Designated-Person Trades

10 recent disclosure(s)

SUDHIR VALIAPledge · 18,00,000
RAKSHA VALIAPledge · 22,00,000
Dilip S. ShanghviAcquisition · 2,52,80,899
RAKSHA VALIAPledge · 19,00,000
Raksha ValiaPledge · 30,80,000
Raksha ValiaPledge · 10,00,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Pref. Allotment19/05/2026 · 3,85,10,000
Company Information
Incorporated2006
ChairmanDilip S Shanghvi
AuditorS R B C & Co LLP
Investor Email[email protected]
🌐 www.sparc.life

📍 Sun Pharma Advanced Res Centre, Akota Road Akota, Vadodara, Gujarat, 390020

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search